STING Agonist Compounds for Stronger Interferon Activation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies lack effective compounds that can activate the Stimulator of Interferon Genes (STING) pathway to enhance immune responses against diseases such as cancer and viral infections.

Innovation Solution

Development of specific compounds, including those of formula (I) and their pharmaceutically acceptable salts, which activate the STING pathway by binding to cyclic dinucleotides or cytosolic DNA, triggering cytokine production and enhancing immune responses.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing therapies are used, then treatment is provided, but effective activation of STING pathway is insufficient

Engineering Contradiction:

ImproveSTING pathway activation efficacyVSAvoidimmune response enhancement

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent modifies molecular parameters of STING activators by presenting specific chemical structures (formula I) with defined substituents (R1-R6, n, X) to optimize binding affinity and signaling efficacy, thereby resolving the insufficient activation problem

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates synthetic compounds that replicate and enhance the natural ligand-function interaction by designing molecules that mimic cyclic dinucleotides or cytosolic DNA while providing superior pharmacological properties

Inventive Principle:

Principle #26Copying

2Productivity

If STING pathway is activated, then immune response is enhanced, but compound specificity and safety must be maintained

Engineering Contradiction:

Improveimmune response enhancementVSAvoidcompound specificity

Core Design Contradiction:

ProductivityVSManufacturing precision

Solution Approach 1:

The patent applies local chemical modifications at specific positions (R1-R6 substituents) to achieve selective STING activation while maintaining overall molecular integrity and safety profile

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The compound structure is divided into distinct functional segments (formula I components) where each segment (R1-R6, n, X) can be independently optimized for specific biological activities and safety characteristics

Inventive Principle:

Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The compounds effectively activate the STING pathway, leading to increased expression of type I interferons and proteins associated with antiviral and antitumor immunity, providing therapeutic benefits for various diseases including cancer and infections.

Implementation Method 1

STING is an endoplasmic reticulum-associated protein that binds to cyclic dinucleotides or cytosolic DNA to trigger cytokine production

Methodology Applied

Scientific EffectMolecular binding:

Implementation Method 2

Initiation of these pathways leads to the expression of type I interferons and proteins associated with antiviral and antitumor immunity

Methodology Applied

Scientific EffectGene expression:

Data Source

PatentUS20260021107A1Stimulator of interferon genes agonists

Publication Date: 2026.01.22 INIMMUNE CORP

AI summary

Stimulator of Interferon Genes (STING) modulators and their use for treating a disease, disorder, or condition associated with STING.